Hematologic Malignancies Market Overview: Key Findings and Strategic Recommendations

 The global hematologic malignancies market size is estimated to reach USD 113.89 billion in 2030 and is projected to grow at a CAGR of 8.0% from 2024 to 2030. Increasing incidence of hematologic malignancies and presence of a strong product pipeline are estimated to boost the market. Moreover, increasing number of mergers and acquisitions are also expected to accelerate growth.

 

Furthermore, governments of developing countries are spending more on healthcare and on improving healthcare infrastructure. This is likely to reduce out-of-pocket expenditure for patients. which is considered as one of the major factors driving the hematologic malignancies market.

 

Recently it has been seen that the government sources are taking an initiative in funding the institutes for breakthrough oncology research. This is a major growth driver for the market as it will support the institutes to conduct their research on a larger-scale without any financial constraints. Federal government funding for research in oncology has led to a substantial development in cancer detection, prevention, diagnosis, treatment and quality of life for patients. Due to the advancement in cancer research, more patients with cancer are being successfully treated. The increasing investment in cancer research is expected to boost the growth of market during forecast period.

 

 

Access the Hematologic Malignancies Market Size, Share & Trends Analysis Report By Disease (Leukemia, Lymphoma), By Therapy (Chemotherapy, Immunotherapy), By End Use, By Region, And Segment Forecasts, 2024 - 2030

 

 

Hematologic Malignancies Market Report Highlights

·        Multiple myeloma is expected to be one of the fastest growing segments over the forecast period owing to strong pipeline of blockbuster products

 

·        Chronic myeloid leukemia was identified as the largest leukemia subtype in 2016 due to availability of large number of products and high number of target population

 

·        Chemotherapy held the largest share in 2016 on the basis of therapy due to its preference as first line of therapy and wide product range

 

·        Immunotherapy is anticipated to be the fastest growing segment and this can be attributed to lower adverse effects and higher efficiency

 

·        North America dominated the market in 2016 owing to local presence of key players and increasing number of mergers and acquisitions

 

·        Asia Pacific is expected to be the fastest growing region over the next decade with lucrative CAGR from 2017 to 2025 due to improving economic conditions and rising healthcare expenditure

 

·        Some of the key players are Pfizer, Inc.; F. Hoffmann-LA Roche Ltd; Sanofi; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited

 

·        Most of the key players are focusing on expanding their product portfolios, development of new treatment, and acquisitions.

 

Key Hematologic Malignancies Company Insights

Some of the key companies in the hematologic malignancies market include Pfizer Inc.; F.Hoffmann-LA Roche Ltd, Novartis AG.; GlaxoSmithKline PLC, Johnson & Johnson. Organizations are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies.

 

Pfizer Inc.; develops and produces medicines and vaccines for human and animal’s treatments such as immunology, cardiology, neurology, etc.

 

F.Hoffmann-LA Roche Ltd; commonly known as Roche operates in two divisions: Pharmaceuticals and diagnostics. Roche specialized in products such as drugs used for cancer treatment against virus and diseases.

 

 

Order your free sample copy of “Hematologic Malignancies Market Report 2024 - 2030, published by Grand View Research

 

 

Key Hematologic Malignancies Companies:

The following are the leading companies in the hematologic malignancies market. These companies collectively hold the largest market share and dictate industry trends.

 

·        Pfizer Inc.

·        F. Hoffmann-LA Roche Ltd

·        Sanofi SA

·        Bristol-Myers Squibb Company

·        AbbVie Inc.

·        Novartis AG

·        GlaxoSmithKline PLC

·        Amgen Inc.

·        Takeda Pharmaceutical Co. Ltd

·        Johnson & Johnson

 

 

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email:  sales@grandviewresearch.com